Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...

Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...

But when your peripheral nerves-those found outside of the brain and spinal cord-are damaged, it can cause pain and numbness ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

No statistical difference was reported in time to onset of CIPN between the 2 groups. Additionally, 75% of the patients undergoing treatment with gemcitabine plus albumin-bound paclitaxel did not ...

A study conducted at the Federal University of São Paulo (UNIFESP) in Brazil has concluded that the use of monochromatic ...

The study was conducted at the Federal University of São Paulo and involved 144 diabetic patients, who were treated with ...

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect for patients undergoing cancer treatments, and ...

Argenx Se (ARGX) has released an update. Argenx SE and Zai Lab Limited have announced that their drug VYVGART Hytrulo has received approval ...

Zai Lab (ZLAB) and Argenx (ARGX) announced that China’s National Medical Products Administration, or NMPA, approved the supplemental ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...